1 May 2024 - The May 2024 issue of the Schedule of Pharmaceutical Benefits is out and now in effect.

The May issue of the Schedule includes several new/revised listings of note:

• Abemaciclib (Verzenio) - new indication
• Amino acid formula with vitamins and minerals without valine, leucine and isoleucine and supplemented with arachidonic acid and docosahexaenoic acid (MSUD Explore5)
• Amino acid formula with vitamins and minerals without methionine and supplemented with arachidonic acid and docosahexaenoic acid (HCU Explore5)
• Amino acid formula with vitamins and minerals without phenylalanine and tyrosine and supplemented with arachidonic acid and docosahexaenoic acid (TYR Explore5)
• Difelikefalin acetate (Korsuvo) - new medicine
• Dostarlimab (Jemperli) - new medicine
• Eltrombopag olamine (Revolade) - new indication x 2
• Mavacamten (Camzyos) - new medicicine
• Risankizumab (Skyrizi) - new strength
• Tafamidis (Vyndamax) - new medicine
• Upadacitinib monohydrate (Rinvoq) - restriction change

Read Summary of PBS changes